IL17A and chronic mucocutaneous candidiasis: Another risk factor for oral candidiasis is IL-17 blockade used to treat inflammatory diseases (Nash et al., 2018); this is an interesting corollary to the pathways implicated in candidate gene studies of chronic mucocutaneous candidiasis (CMC), as discussed in the section on “idiopathic” infections by Candida spp.